Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Zhongzhi Pharmaceutical Holdings Limited ( (HK:3737) ) just unveiled an update.
Zhongzhi Pharmaceutical Holdings Limited has warned investors that its net profit for the year ended 31 December 2025 is expected to decline by more than 70% compared with 2024, based on a preliminary review of its unaudited consolidated management accounts. The company attributed the sharp earnings drop mainly to short-term sales revenue pressure stemming from adjustments to industry policies, which have weighed on profitability, but said it will continue to invest in market development and actively seek new business growth drivers, while advising shareholders and potential investors to exercise caution in trading its shares ahead of the formal annual results announcement due by the end of March 2026.
The most recent analyst rating on (HK:3737) stock is a Buy with a HK$0.80 price target. To see the full list of analyst forecasts on Zhongzhi Pharmaceutical Holdings Limited stock, see the HK:3737 Stock Forecast page.
More about Zhongzhi Pharmaceutical Holdings Limited
Zhongzhi Pharmaceutical Holdings Limited is a Hong Kong-listed pharmaceutical group engaged in the development, production and sale of pharmaceutical products, operating through a number of subsidiaries with a focus on the broader healthcare and drug markets in Mainland China and the region.
Average Trading Volume: 611,815
Technical Sentiment Signal: Sell
Current Market Cap: HK$609.8M
Learn more about 3737 stock on TipRanks’ Stock Analysis page.